Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

18F-Fluorocholine PET/MRI in Restaging of Prostatic Carcinoma in Relation to PSA Level and Detection of Active Disease

J. Ferda, E. Ferdová, J. Baxa, J. Fínek, O. Topolčan,

. 2018 ; 38 (7) : 4139-4143.

Jazyk angličtina Země Řecko

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc18033018

AIM: To evaluate our own experience with 18F- fluoromethylcholine-(FCH)-positron-emission tomography combined with magnetic resonance imaging (PET/MRI) in restaging of patients with prostatic carcinoma and elevated serum prostate-specific antigen (PSA) level. PATIENTS AND METHODS: The analysis was performed on a sample of 100 male patients who underwent 18F-FCH-PET/MRI, with a mean age of 63.2 years (range=47-78 years). The imaging was performed using an integrated PET/MRI hybrid system after intravenous application of 18F-FCH at a dose of 1.25 MBq/kg. The number and sites of pathological accumulation of FCH related to local recurrence, nodal spread and skeletal metastases were compared to corresponding MRI findings; furthermore, the relation of PSA level and presence of FCH accumulation in tumorous tissue was assessed; finally we correlated the findings of different sites of metastatic involvement. RESULTS: In patients with a PSA level up to 2 ng/ml, accumulation in tumorous tissue of local recurrence or metastases was found in 83.33% in cases of biochemical relapse, and in patients with PSA level above 5 ng/ml in 100% of cases. In general, we found any finding explained rise of PSA level in 94% of patients. CONCLUSION: 18F-FCH-PET/MRI using an integrated system with 1,25 MBq/kg dosing of FCH is a valuable tool in evaluation of restaging in patients with prostatic carcinoma, with high detection rate even in those with a low serum PSA level.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc18033018
003      
CZ-PrNML
005      
20181009105646.0
007      
ta
008      
181008s2018 gr f 000 0|eng||
009      
AR
024    7_
$a 10.21873/anticanres.12705 $2 doi
035    __
$a (PubMed)29970541
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a gr
100    1_
$a Ferda, Jiří $u Department of Imaging Methods, Charles University Hospital Pilsen, Pilsen, Czech Republic ferda@fnplzen.cz.
245    10
$a 18F-Fluorocholine PET/MRI in Restaging of Prostatic Carcinoma in Relation to PSA Level and Detection of Active Disease / $c J. Ferda, E. Ferdová, J. Baxa, J. Fínek, O. Topolčan,
520    9_
$a AIM: To evaluate our own experience with 18F- fluoromethylcholine-(FCH)-positron-emission tomography combined with magnetic resonance imaging (PET/MRI) in restaging of patients with prostatic carcinoma and elevated serum prostate-specific antigen (PSA) level. PATIENTS AND METHODS: The analysis was performed on a sample of 100 male patients who underwent 18F-FCH-PET/MRI, with a mean age of 63.2 years (range=47-78 years). The imaging was performed using an integrated PET/MRI hybrid system after intravenous application of 18F-FCH at a dose of 1.25 MBq/kg. The number and sites of pathological accumulation of FCH related to local recurrence, nodal spread and skeletal metastases were compared to corresponding MRI findings; furthermore, the relation of PSA level and presence of FCH accumulation in tumorous tissue was assessed; finally we correlated the findings of different sites of metastatic involvement. RESULTS: In patients with a PSA level up to 2 ng/ml, accumulation in tumorous tissue of local recurrence or metastases was found in 83.33% in cases of biochemical relapse, and in patients with PSA level above 5 ng/ml in 100% of cases. In general, we found any finding explained rise of PSA level in 94% of patients. CONCLUSION: 18F-FCH-PET/MRI using an integrated system with 1,25 MBq/kg dosing of FCH is a valuable tool in evaluation of restaging in patients with prostatic carcinoma, with high detection rate even in those with a low serum PSA level.
650    _2
$a adenokarcinom $x diagnostické zobrazování $x patologie $7 D000230
650    _2
$a senioři $7 D000368
650    _2
$a cholin $x analogy a deriváty $7 D002794
650    _2
$a radioizotopy fluoru $7 D005462
650    _2
$a lidé $7 D006801
650    _2
$a magnetická rezonanční tomografie $x metody $7 D008279
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a multimodální zobrazování $x metody $7 D064847
650    _2
$a staging nádorů $x metody $7 D009367
650    _2
$a pozitronová emisní tomografie $x metody $7 D049268
650    _2
$a prostatický specifický antigen $7 D017430
650    _2
$a nádory prostaty $x diagnostické zobrazování $x patologie $7 D011471
650    _2
$a radiofarmaka $7 D019275
655    _2
$a časopisecké články $7 D016428
700    1_
$a Ferdová, Eva $u Department of Imaging Methods, Charles University Hospital Pilsen, Pilsen, Czech Republic.
700    1_
$a Baxa, Jan $u Department of Imaging Methods, Charles University Hospital Pilsen, Pilsen, Czech Republic.
700    1_
$a Fínek, Jindřich $u Department of Oncology and Radiotherapy, Charles University Hospital Pilsen, Pilsen, Czech Republic.
700    1_
$a Topolčan, Ondřej $u Immunoanalytic Laboratory, Charles University Hospital Pilsen, Pilsen, Czech Republic.
773    0_
$w MED00000478 $t Anticancer research $x 1791-7530 $g Roč. 38, č. 7 (2018), s. 4139-4143
856    41
$u https://pubmed.ncbi.nlm.nih.gov/29970541 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20181008 $b ABA008
991    __
$a 20181009110134 $b ABA008
999    __
$a ok $b bmc $g 1339987 $s 1030012
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2018 $b 38 $c 7 $d 4139-4143 $i 1791-7530 $m Anticancer research $n Anticancer Res $x MED00000478
LZP    __
$a Pubmed-20181008

Najít záznam

Citační ukazatele

Pouze přihlášení uživatelé

Možnosti archivace